Miguéns Suárez, PabloMartelo Vidal, LauraVázquez Mera, SaraNieto Fontarigo, Juan JoséSalgado Castro, Francisco JavierGonzález Barcala, Francisco Javier2026-03-232026-03-232025-11-27Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ and González-Barcala FJ (2025) Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. Front. Immunol. 16:1654111. doi: 10.3389/fimmu.2025.1654111https://hdl.handle.net/10347/46467Background: Blood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms. The aim of this work is to study the effect of mepolizumab in the activation status and functional phenotype of circulating eosinophils. Methods: Samples from healthy controls (N = 15) and patients with severe eosinophilic asthma (N = 15) before and after 4, 16 and 32 weeks of mepolizumab treatment (anti-IL5 mAb; 100 mg s.c./4 weeks) were screened. Demographic, clinical, hematological and biochemical characteristics were collected. Activation and functional phenotype of peripheral blood eosinophils was analyzed by flow cytometry. sCD62L in serum was measured by ELISA. Target mRNAs were quantified by Nanostring. Results: Eosinophils from severe eosinophilic asthma patients showed a higher activation profile (CD11b, CD44 and IL-5Rα expression) compared to healthy subjects. Mepolizumab treatment reduced the number of basophils and eosinophils in peripheral blood. We also found a clear downmodulation on the surface expression (% and MFI) of CD44 and IL-3Rα on eosinophils at week 4, which was maintained through all treatment period (4–32 weeks). The functional phenotype of the remaining eosinophils was also modified with the treatment, showing a reduction of inflammatory eosinophils (iEOS; CD62Llo) percentage without affecting the balance of regulatory subpopulations (CD16dim/hi eosinophils). This was accompanied by a decrease in serum sCD62L levels. mRNA and protein levels showed similar trends for some targets (e.g., IL-5Rα) but not for others (e.g., CD62L). Conclusions: Mepolizumab treatment modifies the functional phenotype of eosinophils resulting in a lower percentage of iEOS and reduced activation status. These changes occur at an early time point (4 weeks) and are maintained throughout all treatment period.eng© 2025 Miguéns-Suárez, Martelo-Vidal, Vázquez-Mera, Blanco-Aparicio, Calvo-Álvarez, González-Fernández, Mosteiro-Añón, Corbacho-Abelaira, Hermida-Valverde, Calvo-Henríquez, Nieto-Fontarigo, Salgado and González-Barcala. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.http://creativecommons.org/licenses/by/4.0/Anti-IL-5 mAbBiologicEosinophil activationEosinophil subsetsIL-5Severe asthmajournal article10.3389/fimmu.2025.16541111664-3224open access